Santhera Pharmaceuticals Holding AG: Santhera Announces Results of Bondholders Meeting
Pratteln, Switzerland, March 9, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces
that while a large majority of 89 % of bondholders represented at yesterday s bondholders meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders may still cast their vote for the resolution that would enable a restructuring of the CHF 60 million 5% Convertible Bonds due 2022.
A total principal amount of CHF 39,130,000 (65%) of the bonds was represented at the meeting and thereof CHF 34,775,000 or 89% voted in favor of the resolution. However, these votes in favor, representing 58% of the total bonds outstanding did not meet the required threshold of 2/3 (or CHF 40 million) for the resolution to be passed. Bondholders who have not yet cast a vote may still do so within a period of a maximum two
German
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pratteln, Switzerland, March 9, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces
that while a large majority of 89 % of bondholders represented at yesterday’s bondholders’ meeting voted in favor of the resolutions proposed by the Company, the required threshold of 2/3 of all bonds outstanding to pass such resolutions was not met. Bondholders may still cast their vote for the resolution that would enable a restructuring of the CHF 60 million 5% Convertible Bonds due 2022.
A total principal amount of CHF 39,130,000 (65%) of the bonds was represented at the meeting and thereof CHF 34,775,000 or 89% voted in favor of the resolution. However, these votes in favor, representing 58% of the total bonds outstanding did not meet the required threshold of 2/3 (or CHF 40 million) for the resolution to be passed. Bondholders who have not ye
(2)
Pratteln, Switzerland, March 3, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD.
The 48-week Phase 2b VISION-DMD study is designed as a pivotal trial to demonstrate efficacy and safety of vamorolone administered orally at doses of 2.0 mg/kg/day and 6.0 mg/kg/day versus prednisone 0.75 mg/kg/day and placebo in ambulant boys aged 4 to
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with .
Santhera Pharmaceuticals Holding AGMarch 3, 2021 GMT Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD.
Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.